Date updated:09-27-2008
Research-and-development spending as a guide for buying stocks.

-
TLAB
Tellabs - $4.41
- +5.00%
- $4.21
Because this R&D-at-a-reasonable-price idea delivered returns amid the Crisis of '08, we screened stocks last week for deeply discounted R&D investments. The result is a contrarian list from which you'd need a strong stomach to buy the high-ranking names: Tellabs (TLAB), Motorola (MOT) and Sun Microsystems (SUNW) have foundered, despite heaps of R&D spending. Their stocks are down by as much as 50% this year.

-
MOT
Motorola Inc - $4.64
- +3.57%
- $4.61
Because this R&D-at-a-reasonable-price idea delivered returns amid the Crisis of '08, we screened stocks last week for deeply discounted R&D investments. The result is a contrarian list from which you'd need a strong stomach to buy the high-ranking names: Tellabs (TLAB), Motorola (MOT) and Sun Microsystems (SUNW) have foundered, despite heaps of R&D spending. Their stocks are down by as much as 50% this year.

-
SUNW
Sunw - $0.00
- N/A
- $N/A
Because this R&D-at-a-reasonable-price idea delivered returns amid the Crisis of '08, we screened stocks last week for deeply discounted R&D investments. The result is a contrarian list from which you'd need a strong stomach to buy the high-ranking names: Tellabs (TLAB), Motorola (MOT) and Sun Microsystems (SUNW) have foundered, despite heaps of R&D spending. Their stocks are down by as much as 50% this year.

-
ISRG
Intuitive Surgica - $122.19
- -2.67%
- $126.28
Companies more expensively valued relative to their R&D, like surgery-robot maker Intuitive Surgical (ISRG) or the operator of Internet-acceleration servers Akamai Technologies (AKAM) offer less scientific bang for the buck.

-
AKAM
Akamai Technologi - $16.45
- +1.67%
- $16.30
Companies more expensively valued relative to their R&D, like surgery-robot maker Intuitive Surgical (ISRG) or the operator of Internet-acceleration servers Akamai Technologies (AKAM) offer less scientific bang for the buck.

-
GOOG
Google Inc. - $334.06
- +1.83%
- $332.50
Being value-minded, like most quants, Mezrich's measure of research value ranks a company higher if it has a history of high R&D spending but is also an unloved stock. Specifically, he adds up a company's last five years of research spending, then divides by the company's current enterprise value. Google and Apple rank low by this standard. They spend a lot on research, but their stocks are expensive.

-
AAPL
Apple Inc. - $93.02
- -1.65%
- $95.96
Being value-minded, like most quants, Mezrich's measure of research value ranks a company higher if it has a history of high R&D spending but is also an unloved stock. Specifically, he adds up a company's last five years of research spending, then divides by the company's current enterprise value. Google and Apple rank low by this standard. They spend a lot on research, but their stocks are expensive.

-
PFE
Pfizer Inc - $17.80
- -1.98%
- $18.32
Pfizer (PFE) and Schering-Plough (SGP) continue to invest in R&D, but have battered shares, so they outrank Wyeth (WYE). Regeneron Pharmaceutical (REGN) rates higher than more richly valued biotechs like Amgen (AMGN) or Vertex Pharmaceuticals (VRTX). The idea here is inspired by the value-investing tradition: Buy a dollar of research for fifty cents.
- Top Professional Portfolios
- 1. Charlie Munger
- 2. Bernard L. Madoff Inve...
- 3. Renaissance Technologies
- 4. Templeton World A (TEMWX)
- 5. Fidelity Select Consum...
- show all
- Top Do-It-Yourself Portfolios
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » HMH1
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » 10 Short Squeezes
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- show all
Investors were spooked on Wednesday as bleak broad-based corporate outlooks and dismal employment data dominated headlines. Stocks experienced their largest drop in more t...
At Stockpickr.com, we strive to keep track of insider purchasing and buybacks each week. Here's the perfect setup in my mind: insiders buying the stock, the company buying ...
The traders of CNBC’s "Fast Money" think the current stock market is a traders' market. In order to play a traders' market, you have to nimble. You also have to know whic...
Pfizer (PFE) CEO Jeff Kindler has hinted that the world’s biggest drugmaker is open to a large-scale acquisition. “The real goal is to grow revenues," he told the Fina...
A. do yourself a big favor and read cramers
books first. no one should be in the
market without some knowledge of how it
works. also, the market may well be over
valued. no one knows. finally, if you
just have to ignore this advice, stay
way away from 2x or 3x etf's. good luck,
mike
A. small trading before thrusday
Analyst Upgrades for Jan. 5, 2009 more
Here is a list of some of the biggest stocks that hit 52-week lows as of Jan. 7, 2009. more
This list consists of stocks with upcoming splits. It will be updated every 2 weeks. more








Comments not available